Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 32 for your search:

Cancer Type/Condition:  childhood extragonadal germ cell tumor
Stage/Subtype:  childhood extragonadal germ cell tumor
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase III Study of Surgery Followed By Compressed Cisplatin, Etoposide, and Bleomycin in Children With Newly Diagnosed Low- or Intermediate-Risk Extracranial Germ Cell Tumors

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 21 at diagnosis
Sponsor: NCI
Protocol IDs: COG-AGCT0132, NCT00053352, AGCT0132

Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 120
Sponsor: Other
Protocol IDs: R01 CA 89395-01, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959

Evaluation of Single Session Stereotactic Body Radiotherapy

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0445, NCT00492817

A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-07-110, SUN08-01, NCT00704054

Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125

Phase I/II Study of MET Tyrosine Kinase Inhibitor PF-02341066 in Children With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI
Protocol IDs: COG-ADVL0912, ADVL0912, NCT00939770

Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 30
Sponsor: Other
Protocol IDs: OHSU-5056, OHSU SOL-08131-L, NCT00983398

Study of a Non-Cross-Resistant Conditioning Regimen Followed By Single or Tandem Autologous Peripheral Blood Stem Cell Transplantation in Patients With Germ Cell Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 10 to 69
Sponsor: NCI
Protocol IDs: UMN-2006LS032, UMN-MT2005-21, UMN-0608M90586, NCT00432094

Phase II Study of Paclitaxel, Ifosfamide, and Carboplatin in Pediatric Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: Under 21 at original diagnosis
Sponsor: NCI
Protocol IDs: COG-AGCT0521, AGCT0521, NCT00467051

10.

Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-Cis-Retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: NYU 05-40 H12853, PBMTC ONC-032P, NCT00528437

11.

Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 3368, NCT00576537

12.

High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 65
Sponsor: Other
Protocol IDs: 2008-0378, NCT00936936

13.

Antineoplaston Therapy in Treating Children With Brain Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458

14.

Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476

15.

Phase I Study of Photodynamic Therapy With Benzoporphyrin Derivative Monoacid Ring A in Patients With Refractory Brain Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: MCW-7594, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647

16.

Phase I Study of Ixabepilone in Young Patients With Refractory Solid Tumors (Closed to Accrual as of 10/4/2007) or Relapsed or Refractory Leukemia

Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: NCI-02-C-0031, 02-C-0031, 5425, NCI-5425, NCT00030108

17.

Phase I Study of Intra-Arterial Melphalan and Mannitol in Patients With Central Nervous System Malignancies

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 months and over
Sponsor: NCI
Protocol IDs: OHSU-1299, OHSU-ONC-98018-L, OHSU-4834, NCT00253721

18.

Phase I Study of AZD2171 in Pediatric Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: PBTC-020, NCT00326664

19.

Phase I Study of Topotecan Hydrochloride by Convection Enhanced Delivery (Intracerebral Clysis) in Patients With Refractory or Progressive Primary Malignant Brain Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 1 and over
Sponsor: NCI
Protocol IDs: CPMC-AAAA-4229, CPMC-14220, NCT00324844

20.

Phase I Study of Cediranib in Pediatric Patients With Refractory or Recurrent Extracranial Malignant Solid Tumors or Acute Myeloid Leukemia

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-06-C-0152, NCI-P6571, NCT00354848, ZENECA-D8480C00016

21.

Phase I Study of Enzastaurin Hydrochloride in Children and Adolescents With Refractory Primary CNS Tumors

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: PBTC-023, PBTC-023, NCT00503724

22.

Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases

Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 2007-0370, NCT00513162

23.

Phase I Study of MK0752 in Young Patients With Recurrent or Refractory CNS Malignancies

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 21
Sponsor: NCI
Protocol IDs: PBTC-024, PBTC-024, NCI-09-C-0112, NCT00572182

24.

A Trial of RAD001 and Avastin in Children With Recurrent Solid Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: RADBEV, NCT00756340

25.

Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 months to 23 years
Sponsor: Other
Protocol IDs: ACH-CNS-001, NCT00876993

Select All on Page

Help with Results

A Service of the National Cancer Institute